Evidence map›Paper›PMID 37396101›Full record

ArticleEcancermedicalscience2023

Short-course radiotherapy for rectal cancer: real-world evidence in Argentina.

Natalia S Tissera, Berenice Freile, Federico Waisberg, Federico Esteso, Mariana Galli, Fernando Sanchez Loria, Romina Luca, Ivana Inés Pedraza, Diego Hernán Enrico, Carolina Chacón and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Ecancermedicalscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06521827 (The Role of Short Course of Palliative Radiation in Metastatic Cancer Rectum), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06521827 nanot yet recruitingnot on this mapstarted 2024, after this paper: background citation

The Role of Short Course of Palliative Radiation in Metastatic Cancer Rectum

TypeinterventionalSponsorAssiut UniversityRan2024 to 2026Enrolled49ConditionsMetastatic Cancer RectumArmsshort course radiotherapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Natalia S TisseraUpper Gastrointestinal Cancer Translational Research Group, Vall´d Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.
Berenice FreileDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
Federico WaisbergDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
Federico EstesoDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
Mariana GalliDepartment of Radiotherapy, Alexander Fleming Institute, CABA C1426, Argentina.
Fernando Sanchez LoriaDepartment of Surgery, Alexander Fleming Institute, CABA C1426, Argentina.
Romina LucaDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
Ivana Inés PedrazaDepartment of Surgery, Alexander Fleming Institute, CABA C1426, Argentina.
Diego Hernán EnricoDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
Carolina ChacónDepartment of Radiotherapy, Alexander Fleming Institute, CABA C1426, Argentina.
Eduardo HuertasDepartment of Surgery, Alexander Fleming Institute, CABA C1426, Argentina.
Matías Rodrigo ChacónDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.
Juan Manuel O'ConnorDepartment of Oncology, Alexander Fleming Institute, CABA C1426, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Short-course radiotherapy (SCRT) of 25 Gy in five daily fractions is a recommended strategy in the neoadjuvant setting for resectable locally advanced rectal cancer (LARC), as well as in cases of metastatic disease for local control. There is scarce information regarding the use of SCRT for patients who have received nonoperative management. Objectives: To describe the characteristics of patients who received treatment with SCRT for LARC and metastatic rectal cancer, toxicity, and the approach after radiation treatment. Methods: This is a retrospective analysis of all patients who underwent SCRT for rectal cancer at the Alexander Fleming Institute from March 2014 to June 2022. Results: In total, 44 patients were treated with SCRT. The majority were male (29, 66%), with a median age of 59 years (interquartile range 46-73). Most patients had stage IV disease (26, 59.1%), followed by LARC (18, 40.9%). Most lesions were located in the middle rectum (30, 68%). The majority of LARC patients underwent SCRT followed by consolidation chemotherapy (ChT) (16/18, 89%), while most patients with metastatic disease underwent SCRT followed by consolidation ChT (14/26, 53.8%). A clinical complete response (cCR) was documented in 8/44, 18.2% of patients. Most patients with LARC and cCR were managed by a watch and wait approach (5/18, 27.7%). Local recurrence was observed in LARC cases (2/18, 11.1%). Patients who underwent SCRT following consolidation ChT were more likely to have adverse events (AEs) than those undergoing induction ChT following SCRT (11/30, 36.7% versus 3/12, 25%, Conclusion: In a subgroup of patients diagnosed with LARC and treated with SCRT followed by ChT, surgical treatment could be omitted after they achieved a cCR. Local recurrence was similar to that reported in a previous study. SCRT is a reasonable option for local disease control in stage IV disease, yielding low toxicity rates. Therefore, decisions must be made by a multidisciplinary team. Prospective studies are necessary to reach further conclusions.

Indexed as

clinical complete responseLatin Americarectal cancershort-course radiotherapywatch and wait

Identifiers

PMID37396101
PMCPMC10310334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.